lundi 25 février 2019

Onco Actu du 25 février 2019

1. BIOLOGIE

Cell death triggers keep cancer at bay in healthy cells [Institute of Cancer Research]

2. ETIOLOGIE

Older biologic age linked to elevated breast cancer risk [NIH]

2.6 ETIOLOGIE - ENVIRONNEMENT

Bayer faces second trial over alleged Roundup cancer risk [Reuters]

3.1 PRÉVENTION - TABAC

Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting [Achieve]

Achieve climbs on data from smoking cessation clinical trial [Fierce Biotech]

3.5 PRÉVENTION - UV

Sunscreen Regulations Haven’t Aged Well [Wired]

4.12 BIOPSIES LIQUIDES

Could we soon be able to detect cancer in 10 minutes? [The Guardian]

4.5 DÉP., DIAG. & PRONO. - COLORECTAL

Exact Sciences Eyes Cologuard Market Expansion After “Landmark Year” [Xconomy]

4.9 DÉP., DIAG. & PRONO. - SEIN

Breast cancer study confirms importance of multi-generational family data to assess risk [ecancerNews]

5. TRAITEMENTS

Prostate cancer patients believe robotic surgery is superior – despite limited evidence [UNSW Sydney]

Retrospective Analysis of Two EORTC Studies Showed That Gastric Acid Suppressants May Negatively Impact Survival Outcomes in Sarcoma Patients Treated With Pazopanib [EORTC]

5.1 TRAITEMENTS - PRÉ-CLINIQUE

Salk scientists uncover how high-fat diet drives colorectal cancer growth [Salk Institute]

5.2 PHARMA

Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity” [EndPoints]

5.2.2 PHARMA - FUSIONS & ACQUISITIONS

Roche enters into definitive merger agreement to acquire Spark Therapeutics [Roche]

Who’s in line for the next big mega-merger? Morningstar handicaps the odds among the top players [EndPoints]

5.2.3 PHARMA - ÉCONOMIE

So you just got a BTD for your top drug? Don’t be surprised to see the enthusiasm fizzle fast among investors [EndPoints]

5.3 TRAITEMENTS - FDA, EMA, NICE...

EMA opens consultation on guideline for advanced therapies in clinical trials [EndPoints]

5.4 TRAITEMENTS - ECONOMIE

The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews [STAT]

6.6 PUBLICATIONS

Open-access pioneer Randy Schekman on Plan S and disrupting scientific publishing [Nature]

6.7.1 IA/BIOINFORMATIQUE

Looking to Technology to Avoid Doctors’ Offices and Emergency Rooms [NY Times]

6.9 CONTROVERSES

Peter Gøtzsche and the antivaxers [Respectful Insolence]